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Background: Pre-operative chemoradiotherapy (CRT) is the standard treatment in clinical stage T3/4 or node
positive rectal cancer. However, there are no established biomarkers that can predict the pathological response and
clinical outcome to CRT.
Methods: Immunohistochemical staining was performed in tissue arrays constructed from core tissue specimens
taken before treatment and from operative specimens from 112 patients who received 5-FU based pre-operative
CRT and surgery. Expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALDH1 were
assessed and correlated with tumor regression grades and disease free survival.
Results: Of the 112 patients (M/F 74/38, median age: 62), 20 (17.9%) patients achieved pathologic complete
remission (pCR). In analyzing the associations between marker expressions and tumor regression grades, high p21
expression at the pretreatment biopsy was significantly associated with non-pCR (p = 0.022) and poor disease free
survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p = 0.002). In the multivariate analysis, high p21
expression level at the pre-treatment biopsy was significantly associated with poor DFS (p = 0.001, HR 6.14; 95% CI
2.03, 18.55). High CD166 expression level at the pretreatment biopsy was also associated with poor DFS (p = 0.003;
HR 5.61; 95% CI 1.81, 17.35).
Conclusion: These show high p21 and CD166 expression at the pretreatment biopsy were associated with tumor
regression and poor prognosis in patients treated with 5-FU based CRT. Larger, prospective and functional studies
are warranted to determine the role of p21 and CD166 as predictive biomarker of response to CRT.
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Since the report of CAO/ARO/AIO-94 trial showing an
improved local recurrence rate and reduced toxicity with
preoperative chemoradiotherapy (CRT), pre-operative
CRT has become the standard treatment option for
clinical stage T3/4 or node positive rectal cancer [1].* Correspondence: hye2@snu.ac.kr; jhkimmd@snu.ac.kr
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reproduction in any medium, provided the orHowever, many patients still suffer recurrence and death
after preoperative CRT and surgery, especially those who
do not respond to the preoperative CRT. The patients
who achieved complete regression after preoperative
CRT attained a 5-year DFS of 86%, whereas patients who
showed low grade of regression showed a 5-year DFS of
not more than 63%, reappraising the need for a predic-
tive marker of response to preoperative CRT [2].
There have been numerous reports on clinical and
pathological biomarkers that can predict response to pre-
operative CRT, suggesting p53, p21, Ki67, bax, bcl-2, thy-
midylate synthase, etc. as predictive markers of response. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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from a relatively small number of patients, their retro-
spective nature and limited availability of archived sam-
ples. There are still no validated biomarkers that can
predict the response to CRT yet.
Recently, the cancer stem cell hypothesis has shed light
on treatment resistance and recurrence of tumors, al-
though the nature of these cells has not been identified
clearly [8,9]. The cancer stem cell is thought to be dor-
mant and resistant to conventional chemotherapy and ra-
diation therapy, which can be attributed to treatment
failure [10]. Several markers of cancer stem cells have
been suggested in various types of cancers in which those
markers may be associated with the response to chemo-
therapy and radiotherapy and disease free survival. How-
ever, few studies have addressed this issue of cancer stem
cell markers as predictive markers for pathologic re-
sponses and treatment outcome in rectal cancer [4,11].
The purpose of our study was to identify predictive
markers, in pre-treatment biopsies, of pathologic complete
response (pCR) to preoperative CRT and disease free sur-
vival (DFS) after preoperative CRT and surgery.
Methods
Study design and statistical analysis
Using a prospectively maintained colorectal cancer data-
base, patients who met the eligibility criteria were retro-
spectively enrolled in this study. Patients were eligible if
1) pathologically diagnosed with rectal adenocarcinoma
at Seoul National University Bundang Hospital between
Jun. 2003 and Dec. 2008, 2) the patients were consent
with the use of pathology slides for research at the time
of diagnosis 3) clinical stage T3/T4 and/or node positive
by rectal MRI and/or endo-rectal ultrasonography, 4) re-
ceived 5-FU-based CRT and surgical resection with cura-
tive aim and 5) had preoperative biopsy slides available.
All candidate variables for histologic marker analysis
were p53, Ki67, TS, BAX, HIF1α, ALDH1, CD166, p21,
EpCAM, CD44, CD133, which were selected due to po-
tential candidates for cancer stem cell markers or histo-
logic prognostic factors according to recent research on
rectal cancer, with consideration of and technical avail-
ability [7,11-17].
The end point was to identify predictive markers, in
pre-treatment biopsies, of pathologic complete response
(pCR) to preoperative CRT and disease free survival
(DFS) after preoperative CRT and surgery.
Patients
The patients who were diagnosed with rectal cancer were
retrospectively enrolled in this study. Eligible patients re-
ceived pelvic radiotherapy with a dose of 45 Gy followed
by a primary tumor boost of 5.4 Gy over a period
of 5.5 weeks. Patients were given choices betweencapecitabine 825 mg/m2 twice daily throughout the ra-
diation period or intravenous bolus 5-FU (400 mg/m2
daily injection for 4 days) and leucovorin (20 mg/m2 daily
injection for 4 days), or to participate in a clinical trial.
Surgery was performed approximately 6 weeks after com-
pletion of CRT. Postoperative chemotherapy was given to
patients in stages 2 and 3 for an additional 4 months ei-
ther with bolus 5-FU and leucovorin or 5-FU, leucovorin
and oxaliplatin (FOLFOX-6). Patients were assessed every
6 months for follow-up, with a physical examination, mea-
surements of carcinoembryonic antigen levels, and chest
and abdominopelvic CT scans for 5 years after surgery.
Specimen characteristics
Tissue samples before (pre-operative endoscopic biopsy)
and after (surgical specimens) CRT were analyzed. The
representative core tissue specimens (2 mm in diameter)
were taken from individual paraffin blocks and rearranged
in new tissue array blocks using a trephine apparatus
(Superbiochips Laboratories, Seoul, Korea).
Assay methods
Immunohistochemistry and evaluation
Array slides were immunohistochemically labeled with
11 commercially available antibodies: p53 (1:200, DAKO
Glostrup, Denmark), Ki67 (1:100, DAKO Glostrup, Denmark),
TS (1:50, Thermo Scientific, MA, USA), BAX (1:200,
Epitomics, CA, USA), HIF1α (1:30, BD Biosciences, MA,
USA), ALDH1 (1:1000, BD Biosciences, MA, USA), p21
(1:300, Spring bioscience, CA, USA), EPCAM (1:200,
abcam,MA,USA), CD44 (1:30 dilution; BD Biosciences,
MA, USA), CD166 (1:100, Leica, Newcastle, UK) and
CD133 (1:70, Abcam, ,MA,USA). Antigen retrieval was
performed by immersing the slides in citrate buffer (pH 6.0)
and microwaving them for 10 minutes. Nonreactive sites
were blocked using 1% horse serum in Tris-buffered saline
(pH 6.0) for 3 minutes. Primary antibodies were applied,
and antibody binding was detected using the avidin-biotin
peroxidase complex (Universal Elite ABC kit PK-6200;
Vectastain, Burlingame, CA) and diaminobenzidine tet-
rahydrochloride solution (Kit HK 153-5 K; Biogenex,
San Ramon, CA).
Immunohistochemical stains for p53, Ki67, TS, BAX,
HIF1α, ALDH1, CD166, p21, EpCAM, CD44, and CD133
were performed in tissue arrays constructed from core tis-
sue specimens taken before treatment and from operative
specimens.
For p53, Ki67, TS, ALDH1, CD166, CD44, bcl2, EGFR,
and CD133, normal colorectal epithelial cells were used
as internal negative controls. We performed immune-
staining without primary antibody for negative control.
Location of staining; nucleus, membranous and/or cyto-
plasmic, were recorded in supplemental table (Additional
file 1: Table S1). Only tumor cells were counted and cells
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166 [11].
The immune-reactivity was recorded as a total per-
centage (%) of positive cells for Ki67. For the other
markers, the staining intensity was scored as follows:
none, 0; weak, 1; moderate, 2; intense, 3 (Figure 1). If
the staining intensity was heterogeneous in a section, itA)
B)
Figure 1 Immunohistochemical staining of p21 and CD166 (x400). A)was scored based on that which was predominantly ob-
served. The percentages of positive cells were assigned
to one of five categories for protein expression: 0, 0-5%;
1, 5–25%; 2, 25–50%; 3, 50–75%; 4, 75-100%. The two
scores were then multiplied to produce a weighted score
for each tumor specimen [4]. Therapeutic responses to
CRT were assessed with the Dworak Grades [18].Staining intensity of p21 B) Staining intensity of CD166.
Table 1 Patient demographics and clinical characteristics
Characteristics Characteristic No (%)
Sex Male 74 (66.1%)
Female 38 (33.9%)
Age Range, median 33 ~ 82, 62



















cN 0 46 (41.1%)
1 48 (42.9%)
2 18 (16.1%)














Circumferential resection margin Median, range (cm) 1.0 (0.01,2.5)
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Frequency data were analyzed with the Chi-square test.
To obtain the appropriate cut-off scores for each marker,
receiver-operating characteristic (ROC) curve analysis
was performed for pathologic complete response [19].
The cut-off score was determined at the point of maxi-
mizing the sum of sensitivity and specificity. Survival
analysis was done with the Kaplan–Meier method, and
the groups were compared with the log-rank test. Uni-
variate and multivariate analyses were performed based
upon the logistic regression or Cox regression model
with forward conditional variable entry (p < 0.05) and re-
moval (p > 0.10). A two sided value of p < 0.05 was con-
sidered as statistically significant.
Ethics
The study protocol was reviewed and approved by the
Institutional Review Board of Seoul National University
Bundang Hospital. The recommendations of the World
Medical Association Declaration of Helsinki for Ethical
Principles for Medical Research Involving Human Sub-
jects were also followed.
Results
Patients’ characteristics
One hundred and sixty one consecutive patients who were
diagnosed with rectal cancer and received 5-FU based
pre-operative CRT were identified from the database.
Among those who received preoperative CRT, 12 patients
did not undergo surgery due to poor medical conditions
or follow-up loss and 8 patients had initially metastatic or
double primary malignant diseases. Eight patients were at
stage I. For two patients, radiation therapy was terminated
early due to complications and 19 patients did not have
any initial pathologic slides available for this study. Finally,
112 patients were enrolled (Additional file 1: Figure S1).
Their median age was 62 years (33 – 82). The characteris-
tics of the patients are presented in Table 1. Chemo-
therapy given during the CRT phase was as follows: 49
received bolus 5-FU and leucovorin, 5 received 5-FU con-
tinuous infusion, 44 received capecitabine, 4 received cap-
ecitabine with irinotecan and cetuximab, and 10 patients
received capecitabine with oxaliplatin. Low anterior re-
section (95.5%) or abdominoperineal resection (4.5%) was
performed at a median of 6.7 weeks (range; 5.1 to 9 weeks)
after CRT. Out of 112 patients, 20 (17.9%) patients
achieved pathologic complete remission (pCR).
Score distributions
All the pre-operative biopsy samples were available but
post–operative surgical samples were available in only 75
patients due to the operations taking place in other hospi-
tals, poor specimen quality or total tumor regression after
CRT. All marker expression scores were classified intohigh or low using cut-off values defined as described
(Additional file 1: Table S2). The sensitivity of each marker
expression according to the cut-off value ranged from
0.099 to 0.637 but the specificity ranged from 0.5 to 1.0.
The mean immune reactivity scores of p53, Ki67,
HIF1α, CD44 and CD133 were higher in the pre-
operative biopsy samples than in the post-operative sur-
gical samples (Additional file 1: Table S3).
Table 3 Multivariable analysis of cell markers and disease
free survival (DFS)
Variables HR (95% CI) p-value
Tumor regression grade 1 1 0.046
Tumor regression grade 2 0.257 (0.079,0.853) 0.024
Tumor regression grade 3 0.065 (0.007,0.604) 0.016
Tumor regression grade 4* <0.001 (NA). 0.999
ypN0 1 0.001
ypN1 9.025 (2.276,35.792) 0.002
ypN2 15.542 (3.634,66.462) 0.001
CD166 5.614 (1.816,17.356) 0.003
p21 6.146 (2.035,18.559) 0.001
*No event (disease recurrence) was observed.
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complete pathologic response
The pathologic complete response was significantly asso-
ciated with Ki67 and p21 expression (p = 0.022. and
0.022, respectively). Among the clinical factors, clinical
stage III and high CEA level exhibited significantly poor
complete pathologic response (p = 0.001 and 0.011, re-
spectively, Additional file 1: Table S4). In the multiva-
riable analysis, clinical stage III, high CEA level and high
p21 expression were independently associated with poor
pathologic responses (Odd ratio, 0.199, 0.422, 0.127 in
clinical stage, CEA level and p21) (Table 2).
Association between marker expression levels and
disease free survivals
The median disease free survival was not reached after a
median follow-up of 48.1 months. Disease recurrence was
observed in 21 patients (18.8%). In the analysis between
clinical factors and disease free survival, low tumor regres-
sion grade, high pathologic T and high pathologic N stage
(ypT and ypN) were significantly associated with short dis-
ease free survival (p < 0.001). In the marker analysis, high
expressions of CD166 and p21 in the pretreatment biopsy
specimens were associated with short disease free survival
(p = 0.045 and 0.002. respectively). The Ki67 expression,
which showed a significant association with the pathologic
complete response, was not associated with disease free
survival (p = 0.667, Additional file 1: Table S5). In the mul-
tivariable analysis, tumor regression grade, ypN, CD166
and p21 expression levels in pre-operative biopsy samples
were significantly associated with disease free survival,
showing that a high expression level of CD166 and p21
exhibited shorter disease free survival (HR 5.614, p = 0.003
in CD166, HR 6.146, p = 0.001 in p21, Table 3, Figure 2).
There was no significant correlation between the p21 ex-
pression levels in the pre-operative samples and clinical
characteristics including age, sex, histologic differentiation
and clinical stage (Additional file 1: Table S6).
Score analysis within the paired samples
In the analysis of scores within the paired samples, there
was a significant score change in Ki67, HIF1α, ALDH1,
CD166, EpCAM and CD44 but not in p53, TS, BAX,
p21 and CD133. The expression scores of Ki67, HIF1αTable 2 Multivariable analysis of marker expression and
clinical factors with pathologic response
Variables p-value OR (95% CI)
Clinical stage 0.028 0.199 (0.056,0.708)
Pre-operative CEA levels 0.044 0.422 (0.084,2.120)
Ki67 0.999 NA
p21 0.021 0.127 (0.022,0.729)
NA: not applicable :low Ki67 – no pCR observed.and CD44 decreased and those of ALDH1, CD166 and
EpCAM increased in the post-operative specimens com-
pared with the scores in the pre-operative specimens
(Table 4, Additional file 1: Figure S2 and Figure S3,).
The change in marker expression levels between before
and after treatment showed no statistical significance on
disease free survival (Additional file 1: Figure S4). Trends
for longer survival with a decrease in CD166 and an in-
crease in p21 levels were observed but the significance
was marginal (p = 0.071 and 0.080 in CD166 and p21).Discussion
The present study showed that high p21 expression level
in the pre-CRT specimen was associated with poor
pathologic regression and worse DFS after CRT. Our
study also showed that expression levels of potential
cancer stem cell markers, especially CD 166, increased
after preoperative CRT and high expression of CD166
was significantly associated with poor DFS.
p21 is known as one of the cell cycle inhibitors which
plays a role through the p53 dependent or independent
pathway. However, little is known about its clinical sig-
nificance, especially with regard to rectal cancer. In
leukemogenesis, p21 expression in leukemic stem cell pre-
serves the cell proliferation ability and protects against
DNA damage by cell cycle inhibition [20]. Its dormancy
with p21 expression may be associated with chemotherapy
resistance. In addition, the role of p21 has been reported
to be important in chemotherapy resistance in cell line ex-
periments in colorectal cancer [21]. These reports support
our results that the initial high expression of p21 was
associated with poor clinical outcome. The trend for bet-
ter disease free survival with the increase in p21 expres-
sion after chemoradiotherapy could be associated with
increased tumor cell cycle inhibition.
In several clinical studies, the role of p21 expression as
a prognostic or predictive factor on survival in rectal
cancer is controversial. One study showed that the post-
A) B)
Figure 2 Disease free survival according to expression of A) p21 and B) CD166. The DFS of high p21 group was 58.9 months (95% CI 44.4,
71.7), low p21, 75.8 months (95% CI 70.8, 80.8), high CD166, 61.6 month (95% CI 49.5, 73.8) and low CD166, 75.2 months (95% CI 69.6, 80.8).
Sim et al. BMC Cancer 2014, 14:241 Page 6 of 8
http://www.biomedcentral.com/1471-2407/14/241CRT p21expression level was associated with survival
but not with the pre-CRT level [13]; however, the treat-
ment was different from the recent standard pre-opera-
tive CRT. Other studies with recent pre-operative CRT
reported that the pre-CRT p21 expression level had
prognostic impact on survival but not the post-CRT
level [22] which supports the results of our study that
shows the consistent significance of the pre-CRT p21
level on predicting the pathologic response and survival
outcome (p = 0.022 and p = 0.021 respectively).
We wanted to test the hypothesis that cancer cells ex-
pressing potential stem cell markers would be a poor
predictive marker of response to preoperative CRT, and
found that high expression of CD166, but not CD 44 or
133, was associated with poor survival outcome. The
increased expression of CD 166 in the postoperative spe-
cimen after CRT was also notable. The proliferationTable 4 Serial analysis of marker expression in patients
who had both pre- and post-operative specimens
(by Wilcoxon signed rank test)
Markers Mean score P-value
Pre-operative specimen Post-operative specimen
p53 7.098 6.845 0.135
Ki67 48.098 21.555 0.001
TS 1.126 1.291 0.661
BAX 4.357 4.943 0.326
HIF1α 1.563 0.591 0.001
ALDH1 1.197 3.507 0.001
CD166 0.478 2.305 0.001
p21 6.357 7.281 0.090
EpCAM 9.985 12.0 0.001
CD44 1.394 0.859 0.028
CD133 3.943 4.309 0.193index was higher in the pre-CRT specimens than in
the postoperative specimens. However, expression of
ALDH1,CD166 and EpCAM, which could represent the
dormant stem cell portion, increased in the post-
operative specimens which are in agreement with pre-
vious reports [23-25]. Although robust marker changes
were not observed between pre- and post- tumors, the
present study showed the trend for enrichment of cells
expressing potential stem cell markers.
There have been numerous reports on the increase in
cancer stem cell markers in post-chemotherapy and/or
radiotherapy specimens in other organs such as breast
cancer, linking the presence of cancer stem cells to re-
sistance to chemotherapy. In colon cancer, CD133 was
the first markers associated with cancer stem cell in
mouse model [26]. Most reports used CD 133 or 44 as
cancer stem cell markers [11,12,15,16]. However, other
reports suggested that CD44, CD166 could be more
robust identifiers than CD133 [16,27]. In rectal cancer,
reports on the meaning of putative cancer stem cell
markers in the chemotherapy and/or radiotherapy have
been scarce.
CD166 is a kind of cell adhesion molecule and is
widely expressed in various tissues, such as neurons,
fibroblasts, endothelial cells, and keratinocytes [28]. Not
much of its function is known in cancer. Several reports
have shown that CD166 was involved in the tumor cell
invasion process by activating the metalloproteinase cas-
cade in response to extensive cell-to-cell and cell-to-
matrix contacts and also suggested CD166 as a potential
marker for tumor invasion and metastasis [28,29]. Other
clinical reports also have suggested CD166 was a puta-
tive marker for radiation resistance and a poor progno-
sis, which corresponded with our results [11,30].
Other markers except p21 and CD166 did not show cli-
nical significance in this study. However, many studies
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CD133 CD44, EpCAM, ALDH1 or HIF1α [4,11,24,31].
This may be attributed to the different type of cancer and
the lack of a standard method for evaluating those
markers as well.
This study has several limitations. First, this was a retro-
spective study and the results were not validated in other
patient groups. Second, all markers were evaluated based
on protein expression levels, not on genetic levels, which
means the results do not reflect molecular changes in can-
cer cells on a genetic level. Third, the method used for in-
vestigating these markers was IHC staining alone This
method may show a wide variety due to methodological
differences and needs standardization before our results
can be widely applied. However, our study comprehen-
sively evaluated marker expression using immunohisto-
chemistry in an attempt to find predictive biomarkers of
response to CRT in a relatively larger number of patients
than before, and in uniformly treated patients at a single
center. The trend for enrichment of cells expressing po-
tential stem cell markers after CRT is notable, which need
further investigation for the possibility of treatment target-
ing these cells. Immunohistochemical staining is a widely
used technique which means this result could have prac-
tical clinical applications. Although it may not be possible
to characterize cancer stem cells by a single marker, our
study results suggest that CD 166 and p21 can be used to
select patients who would less likely benefit from pre-
operative CRT in rectal cancer. This study cannot over-
come the defects that previous studies have. However, the
results can call attention to the old but potential markers,
p21 and CD166 as useful selection markers with new
perspectives.
Conclusion
In summary, high p21 expression was associated with non-
complete pathologic response and poor disease free sur-
vival outcome in patients with 5-FU based CRT. High
CD166 expression was associated with poor prognosis but
the association with non-complete pathologic response
was not significant. Larger, prospective trials and functional
studies are warranted to determine the role of p21 as a pre-
dictive biomarker of response to chemoradiotherapy.
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